Thryv Therapeutics Announces the Appointment of Esteemed Executive Leader Amy Sehnert, MD, as Chief Medical Officer
The Californer/10297886

MONTREAL, Nov. 20, 2024 ~ Thryv Therapeutics Inc., a clinical-stage biotechnology company, has recently announced the appointment of Dr. Amy Sehnert as their new Chief Medical Officer (CMO). With her extensive experience in pediatric cardiology and her background in innovative biotech companies, Dr. Sehnert will lead the clinical development and strategy for Thryv Therapeutics' expanding cardiometabolic product portfolio.

Dr. Sehnert brings over 20 years of experience as a serial and founding medical lead at various biotech companies, where she has introduced precision diagnostics and therapeutics to the clinic. Most recently, she served as Vice President and Global Program Lead for cardiovascular assets at Bristol Myers Squibb (BMS). During her time at BMS, she played a crucial role in the development and approval of Camzyos®, a groundbreaking treatment for hypertrophic cardiomyopathy (HCM). Her contributions to this development ultimately led to BMS's acquisition of MyoKardia, Inc. for $14 billion in 2020.

Expressing her excitement about joining Thryv Therapeutics, Dr. Sehnert said, "I am thrilled to join Thryv Therapeutics at such an important time in the company's journey. Thryv Therapeutics' cutting-edge approach to cardiovascular diseases aligns with my passion for advancing precision medicine, and I look forward to working with the team to deliver transformative therapies to patients worldwide."

More on The Californer

• Charleston, SC - ACSEC offers Rain Barrels Through Annual Program
• HAVAS CHICAGO APPOINTS FRANK DATTALO AS CHIEF CREATIVE OFFICER
• Greek Government Issues Landmark Ministerial Order Addressing Citizenship of Greek-born adoptees
• Stout Surpasses 60,000 Acres and 3 Billion Plants Scanned
• OpsVeda Announces Launch of TariffSight, the World's First Comprehensive Platform to Address Tariff-Driven Challenges

Aside from her work in cardiovascular diseases, Dr. Sehnert has also made significant contributions in other fields of medicine such as maternal-fetal health, oncology, and genomics. She was one of the early pioneers in non-invasive prenatal testing (NIPT) and cell-free DNA applications that are now widely used in clinical settings.

Dr. Sehnert holds a Doctor of Medicine degree from the University of Minnesota and completed her residency in Pediatrics at the University of Colorado. She also completed a fellowship in Pediatric Cardiology at UCSF and has held faculty appointments at both UCSF and Stanford University. In 2022, she was recognized as one of the Most Influential Women in Business by the San Francisco Business Times and among the Top 25 Healthcare Technology Leaders of San Francisco. She has co-authored over 60 peer-reviewed publications and is considered an internationally recognized expert in her field.

Thryv Therapeutics' CEO, Paul F. Truex, expressed his excitement about Dr. Sehnert joining the team, saying, "On behalf of Thryv Therapeutics, I am excited to welcome Amy to the team. Her extensive experience in designing and executing late-stage clinical trials for genetic and broader cardiovascular diseases, along with her leadership qualities, will be invaluable as we enter the next phase of clinical development for our SGK1 portfolio."

More on The Californer

• UC Ventures Appoints Julie Chang as Managing Director of Investments
• MAJOR New release of Krypto500 (ELF-HF) Sigint - COMINT software
• New Build-to-Suit VA Medical Office Facility Coming to Highland Heights, KY
• Armed With Purpose and Trained To Lead
• Introducing the Heart-Shaped Pearl Earrings — A Romantic New Addition from Sairahaz Jewelers

Dr. Philip Sager, Thryv Therapeutics' founding Chief Medical Officer, will continue to provide strategic clinical and regulatory guidance as the company's portfolio advances into later stage clinical studies. Truex also expressed his gratitude for Dr. Sager's contributions to Thryv Therapeutics' portfolio thus far and his commitment to finding treatments for patient communities.

In conclusion, Thryv Therapeutics is excited to have Dr. Amy Sehnert join their team as their new Chief Medical Officer. With her expertise and experience in precision medicine and clinical development, she will play a crucial role in advancing Thryv Therapeutics' cardiometabolic product portfolio targeting serum glucocorticoid inducible kinase 1 (SGK1).

---

Show All News | Report Violation